Comparison of simultaneous integrated tumor bed boost and sequential boost during conventional fractionated whole-breast irradiation after breast-conserving surgery
Dan-Qiong Wang
,
Yu-Chun Song
,
Zi-Han Qiu
,
Hao Jing
,
Hui Fang
,
Yu Tang
,
Yong-Wen Song
,
Yue-Ping Liu
,
Shu-Nan Qi
,
Yuan Tang
,
Ning-Ning Lu
,
Bo Chen
,
Yi-Rui Zhai
,
Wen-Wen Zhang
,
Xin Liu
,
Si-Ye Chen
,
Zhuan-Bo Yang
,
Guang-Yi Sun
,
Xu-Ran Zhao
,
Zhi-Hui Zhang
,
Ye-Xiong Li
,
Shu-Lian Wang
Comparison of simultaneous integrated tumor bed boost and sequential boost during conventional fractionated whole-breast irradiation after breast-conserving surgery
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Corresponding author:
yexiong12@163.com
wangsl@cicams.ac.cn
Show less
History+
Received
Accepted
Published Online
2025-12-06
2026-04-28
2026-11-17
PDF
(778KB)
i
This article has been updated.A Correction to this article was published on .
To compare the safety and efficacy of simultaneous integrated boost (SIB) and sequential boost (SeB) during conventional fractionated whole-breast irradiation (CF-WBI) after breast-conserving surgery. In total, 362 patients receiving CF-WBI following SeB and 272 receiving CF-WBI with SIB between 2010 and 2018 were included. All patients received 50 Gy in 25 fractions to the whole breast, with either 60 Gy in 25 fractions (SIB) or 10 Gy in 5 fractions (SeB) to the tumor-bed. Toxicities were assessed by CTCAE v3.0, and cosmetic outcomes by the Harvard scale. The outcomes analyzed included survival outcomes, treatment-related toxicities, and cosmetic outcomes. After a median follow-up of 92 months, no significant differences were observed between SIB and SeB in 5-year local control (LC) (98.2% vs. 97.8%), local-regional control (LRC) (95.6% vs. 97.1%), disease-free survival (DFS) (95.2% vs. 93.1%), overall survival (OS) (98.9% vs. 98.0%), and breast-conserving surgery(BCS) (99.3% vs. 98.6%). Inverse probability of treatment weighting (IPTW) analyses confirmed these findings. Rates of breast induration, fair or poor cosmesis result, and grade ⩾ 2 skin toxicity, pneumonitis, breast swelling, breast pain, lymphedema, and shoulder mobility were comparable between groups. Compared with SeB, SIB is an alternative approach with comparable survival outcomes and toxicities but a short treatment period. Further follow-up is needed to assess long-term outcomes.
This article has successfully passed peer review and final editorial review, and will soon enter typesetting, proofreading and other publishing processes. The currently displayed version is the accepted final manuscript. The officially published version will be updated with format, DOI and citation information upon launch. We recommend that you pay attention to subsequent journal notifications and preferentially cite the officially published version. Thank you for your support and cooperation.